StockAnalyzer

Financial Analysis

DashboardSectorsComparablesScreenerUniverseMicrocapsAI 2nd OrderTheme MapEnergy & MaterialsMacroWatchlistCompareMi CarteraPortfolio

Recent

v0.1
INDISA.SN$2713.30+0.49%
Fair $2713.30+0.0%

INDISA.SN

Instituto de Diagnóstico S.A.

Healthcare / Medical Care FacilitiesSantiago

$2713.30

+13.30 (+0.49%)

Fairly Valued+0.0%Fair Value $2713.30Fund rank 33/100 · Data gapFallback financials|
SA 59/C
F-Score: 5/9

FCF base 3Y

n/d

n/d CAGR · yield n/d

FCF base 5Y

n/d

n/d base · n/d expected

Precio de entrada

n/d

MOS 26% · confianza 25%

FCF escenarios

weak_data · normalized FCF $16.6B · quality 60.7/100

Data gap 33/100
Bear 5Yn/dn/d
Base 5Yn/dn/d
Bull 5Yn/dn/d
Return 0/100Downside 20/100Model quality 49/100Data QA 20/100

Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.

Quality + valuation scorecard

SA Score

59/100

C

Piotroski

5/9

balance/quality

Valuation

50/100

+0.0% upside

5Y CAGR

+0.0%

50/100

Data QA

16/100

SEC 0%

Latest source: unknownPeriods: 4Warnings: 0unknown: 4
No SEC-backed annual rows; valuation uses fallback financial data. Insufficient audited annual history (<3 SEC-backed years); composite fair value and forward targets are disabled until manually verified.
Thesis & Journal · INDISA.SNLocal privado en este navegador · Instituto de Diagnóstico S.A.
Plantilla tipo buy-side: tesis, bull/base/bear, catalizadores, riesgos, kill criteria y fecha de revisión. Esto no gasta GPT-5.5; luego lo usamos como contexto del memo.

Sin guardar todavía.

Market Cap

$416.3B

P/E

24.9x

↑

EV/EBITDA

14.6x

↑

ROE

7.6%

↑

Gross Margin

26.0%

↓

Debt/Equity

0.48

↑
52-Week Range$2713
$2041$2936

TradingView lightweight chart

INDISA.SN price, volumen y niveles de valoración

Último $2,713Periodo +5115.4%
Fair value: $2,713

Price & Ratios

Absolute Values (Left Axis)

Ratios / Percentages (Right Axis)

Financial statement dashboard

Crecimiento, márgenes y provenance

2022–2025 · 3 años de histórico normalizado

Revenue CAGR

+12.5%

FCF CAGR

—

FCF margin

7.9%

FCF / Net income

1.38x

Latest source

Provider fallback

Margin decomposition

Último año: revenue $272.31B · net income $15.66B · FCF $21.64B

2022-FY → 2025-FY

Gross margin

26.0%+2.2% pts

Operating margin

4.6%-2.2% pts

Net margin

5.8%-1.1% pts

FCF margin

7.9%+9.2% pts
MetricTTM
2025
2024
2023
2022
Income Statement
Revenue$272.31B$272.31B$239.07B$218.93B$191.29B
Net Income$15.66B$15.66B$7.28B$144.3M$13.05B
EBITDA$32.32B$32.32B$16.53B$7.10B$18.44B
EPS109.00109.0050.560.9790.42
Gross Margin26.0%26.0%24.3%20.5%23.8%
Operating Margin4.6%4.6%6.1%1.9%6.8%
Net Margin5.8%5.8%3.0%0.1%6.8%
Balance Sheet
Debt/Equity0.480.480.951.111.11
Current Ratio1.131.13———
Cash Flow
Free Cash Flow$21.64B$21.64B$16.65B$9.30B$-2.36B
Returns
ROE7.6%7.6%6.7%0.1%12.8%
Valuation
P/E24.8724.8731.051299.0917.80
EV/EBITDA14.6114.6119.4140.1818.00
P/B1.881.882.081.762.29
Growth & Yield
Revenue Growth13.9%13.9%9.2%14.5%—
EPS Growth115.6%115.6%5100.0%-98.9%—
Dividend Yield1.6%1.6%———

Revenue, Net Income & Free Cash Flow ($B)

Margins (%)

Returns (%)

Leverage & Liquidity

Reverse DCF · market-implied EPS growthterminal P/E 15.0x · COE 10.0%

3Y implied EPS CAGR

30.2%

muy exigente

EPS terminal req.

$240.76

Spread vs growth

85.4%

5Y implied EPS CAGR

21.7%

exigente

EPS terminal req.

$291.32

Spread vs growth

93.9%

10Y implied EPS CAGR

15.7%

exigente

EPS terminal req.

$469.17

Spread vs growth

99.9%

Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.

Return attribution · 1Y approxreconcilia total +33.9%

Total return

+33.9%

Start / end P/E

40.5x → 24.9x

EPS bridge

50.56 → 109.00

Residual

-44.6%

EPS growth+115.6%
Multiple rerating-38.6%
Dividend+1.6%
Residual / FX / buybacks / cross-term-44.6%

Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.